MG
CNTX icon

Michael Gelband’s Context Therapeutics CNTX Stock Holding History

Michael Gelband’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-24,750
Closed -$50K – 1681
2024
Q2 		$50K Buy
+24,750
New +$42.7K ﹤0.01% 1448

Other funds holding CNTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return

Michael Gelband's CNTX Position: Q3 2024 in Review

Michael Gelband sold out of Context Therapeutics (CNTX) in Q3 2024, closing a stake of 24,750 shares — an estimated $50K sold.

Michael Gelband first reported a position in CNTX in Q2 2024 and held it in 1 quarter. The position peaked at $50K in Q2 2024. 42 funds tracked by Wall St. Rank hold CNTX as of Q3 2024.

  • Michael Gelband reported no remaining Context Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Michael Gelband sold 24,750 Context Therapeutics shares in Q3 2024, an estimated $50K.
  • Michael Gelband first reported a position in Context Therapeutics in Q2 2024 and held it in 1 quarter.
  • Michael Gelband's Context Therapeutics position peaked at $50K in Q2 2024.
  • 42 funds tracked by Wall St. Rank held Context Therapeutics as of Q3 2024.

Based on ExodusPoint Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.